Form D · Biotechnology
Cellibre, Inc.
San Diego, CA · CIK 0001781232
Offering snapshot reported Oct 9, 2024 · SEC filing
- Reported sold
- $6.71M Offering amount: $23.2M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $521 Reported outside-investor minimum
- First sale
- Sep 30, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2024 | Initial | $6,707,314 | No comparison | 31 | SEC filing |
| Sep 8, 2021 | Initial | $9,873,243 | No comparison | 35 | SEC filing |
| Jul 1, 2019 | Initial | $4,188,000 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526229
Source: Form D, filed Oct 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicky Caiazza | Director, Executive |
| Benjamin Chiarelli | Director, Executive |
| Spiros Kambourakis | Director, Executive |
| Scott Zingheim | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6825 Flanders Drive
San Diego, CA, 92121
San Diego, CA, 92121